Brief: Rezolute To Commence Study Start-Up Activities In US

Rezolute

09/09/2024 12:33

Sept 9 (Reuters) - Rezolute Inc  RZLT.O :
    * FDA LIFTS PARTIAL CLINICAL HOLDS ON RZ358 FOR THE
TREATMENT OF
CONGENITAL HYPERINSULINISM AND AUTHORIZES U.S. INCLUSION IN
ONGOING PHASE 3 STUDY
    * REZOLUTE INC - TO COMMENCE STUDY START-UP ACTIVITIES IN
U.S.
    * REZOLUTE INC - U.S. ENROLLMENT FOR SUNRIZE STUDY EXPECTED
TO
BEGIN EARLY 2025
    * REZOLUTE INC - POTENTIAL U.S. ENROLLMENT TO BEGIN IN EARLY
2025
WILL ENABLE ANNOUNCEMENT OF TOPLINE DATA FROM STUDY IN SECOND
HALF OF 2025

Source text for Eikon:  ID:nGNX7bqdNW 
Further company coverage:  RZLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))